EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)

被引：0
|
作者：
Stefano Fanti
Jolanta Kunikowska
Jochen Walz
Wim Witjes
Anders Bjartell
机构：
[1] IRCCS AOU di Bologna,Nuclear Medicine Division
[2] University of Bologna,Department of Nuclear Medicine
[3] Medical University of Warsaw,Department of Urology
[4] EANM,Department of Urology
[5] Institut Paoli-Calmettes Cancer Center,Department of Translational Medicine, Medical Faculty
[6] EAU Research Foundation,undefined
[7] Skåne University Hospital,undefined
[8] Lund University,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2022年 / 49卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3328 / 3329
页数：1
相关论文
共 50 条
  • [21] Clinical dosimetry in [177Lu]Lu-PSMA therapy: fewer imaging time points, still useful
    De Vries-Huizing, D.
    Rijkhorst, E.
    Owers, E.
    De Wit-Van der Veen, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S126 - S126
  • [22] Higher SUV mean in baseline F18-PSMA 1007 PET is associated with longer survival in patients undergoing Radioligand Therapy with [177Lu]Lu-PSMA I&T
    Huettmann, Thomas
    Hartrampf, Philipp
    Seitz, Anna
    Kuebler, Hubert
    Serfling, Sebastian
    Buck, Andreas
    Werner, Rudolf
    Schloetelburg, Wiebke
    Michalski, Kerstin
    Schirbel, Andreas
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [23] Mathematic Modeling of Tumor Growth During [177Lu]Lu-PSMA Therapy: Insights into Treatment Optimization
    Zaid, Nouran R. R.
    Bastiaannet, Remco
    Hobbs, Rob
    Sgouros, George
    JOURNAL OF NUCLEAR MEDICINE, 2025, 66 (01) : 84 - 90
  • [24] Quantifying the impact of residual activity on therapeutic index: an updated dosimetric comparison between [177Lu]Lu-PSMA-10.1 and [177Lu]Lu-PSMA I&T
    Rinscheid, A.
    Dierks, A.
    Kircher, M.
    Pfob, C.
    Bundschuh, R. A.
    Lapa, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S811 - S812
  • [25] Prognostic implications of dual tracer PET/CT: additional FDg PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
    Michalski, K.
    Ruf, J.
    Meyer, P.
    Buck, A.
    Lapa, C.
    Hartrampf, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S694 - S694
  • [26] 177Lu–PSMA-PET extends survival
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2021, 18 : 542 - 542
  • [27] Impact of [177Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [68Ga]Ga-PSMA-11-PET/CT
    Groener, Daniel
    Wichert, Jennifer
    Adams, Magdalena
    Mader, Nicolai
    Klimek, Konrad
    Ngoc, Christina Nguyen
    Baumgarten, Justus
    Happel, Christian
    Mandel, Philipp
    Chun, Felix K. H.
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    CANCERS, 2023, 15 (15)
  • [28] Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
    Michalski, Kerstin
    Ruf, Juri
    Goetz, Christian
    Seitz, Anna Katharina
    Buck, Andreas K.
    Lapa, Constantin
    Hartrampf, Philipp E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (06) : 2024 - 2030
  • [29] 177Lu–PSMA-PET extends survival
    Peter Sidaway
    Nature Reviews Urology, 2021, 18 : 510 - 510
  • [30] Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy
    Kerstin Michalski
    Juri Ruf
    Christian Goetz
    Anna Katharina Seitz
    Andreas K. Buck
    Constantin Lapa
    Philipp E. Hartrampf
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 2024 - 2030
12345